STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCVX
  4. [Form 4] Vaxcyte, Inc. Insider Trading Activity

Vaxcyte (PCVX) director granted RSUs, 6,750 stock options on Jan. 15

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vaxcyte, Inc. director Olivier Brandicourt reported receiving new equity awards. On January 15, 2026, he was granted 1,357 shares of Common Stock underlying restricted stock units, which will fully vest on the earlier of June 12, 2026 or the day before the next annual stockholder meeting, subject to his continuous service.

He was also granted a stock option for 6,750 shares of Common Stock, which vests monthly and will be fully vested on the same schedule, also conditioned on continued service. After the RSU grant, he directly beneficially owned 2,505 shares of Common Stock, and he held 6,750 stock options.

Positive

  • None.

Negative

  • None.
Insider BRANDICOURT OLIVIER
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 6,750 $0.00 --
Grant/Award Common Stock 1,357 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 6,750 shares (Direct); Common Stock — 2,505 shares (Direct)
Footnotes (1)
  1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BRANDICOURT OLIVIER
(Last) (First) (Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, SUITE 300
(Street)
SAN CARLOS CA 94070
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/15/2026 A 1,357 A(1) $0 2,505 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $48.04 01/15/2026 A 6,750 (2) 06/12/2035 Common Stock 6,750 $0 6,750 D
Explanation of Responses:
1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Remarks:
Olivier Brandicourt, by /s/ Peter N. Efremenko, Attorney-In-Fact 01/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Vaxcyte (PCVX) report for Olivier Brandicourt?

Vaxcyte reported that director Olivier Brandicourt received equity awards on January 15, 2026, including restricted stock units and a stock option to buy Common Stock.

How many RSUs did Vaxcyte director Olivier Brandicourt receive in this Form 4?

He received 1,357 restricted stock units (RSUs), each representing the right to receive one share of Vaxcyte Common Stock, subject to vesting and continued service conditions.

What stock options were granted to Olivier Brandicourt by Vaxcyte?

He was granted a stock option for 6,750 shares of Vaxcyte Common Stock. The option was awarded at no cost to him and is exercisable for 6,750 underlying shares.

When do Olivier Brandicourt’s Vaxcyte RSUs and options fully vest?

Both the 1,357 RSUs and the 6,750-share stock option will fully vest on the earlier of June 12, 2026 or the day prior to Vaxcyte’s next annual meeting of stockholders, subject to acceleration and his continuous service.

How does the stock option for Olivier Brandicourt vest over time?

The 6,750-share stock option vests monthly and will be fully vested by the earlier of June 12, 2026 or the day before the next annual meeting of stockholders, assuming he continues in service.

How many Vaxcyte shares does Olivier Brandicourt own after these grants?

After the reported RSU grant, he beneficially owned 2,505 shares of Common Stock directly, and he held a stock option for 6,750 shares.